Thomas W. Beetham's most recent trade in Viridian Therapeutics Inc was a trade of 3,048 Common Stock done at an average price of $30.2 . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Thomas W. Beetham | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.19 per share. | 03 Mar 2026 | 3,048 | 13,361 (0%) | 0% | 30.2 | 92,019 | Common Stock |
| Viridian Therapeutics Inc | Thomas W. Beetham | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 225,814 | 225,814 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Thomas W. Beetham | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 37,636 | 37,636 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Thomas W. Beetham | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 23.41 per share. | 27 Sep 2024 | 5,000 | 6,000 (0%) | 0% | 23.4 | 117,050 | Common Stock |